The earnings call transcript details post-SSAE sale financials, with 60% adjusted gross margin and 13% EBITDA for the first half of 2024. Future growth is expected in 2025, focusing on cell processing products and market leadership without affecting margins.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing